Avricore Health Inc V.AVCR

Alternate Symbol(s): AVCRF

Technology Diagnostics & Research Information Technology Services

Avricore Health Inc. is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at advancing pharmacy practice and patient care. The Company is involved in the business of health data and point-of-care technologies (POCT). HealthTab, its flagship offering, is a turnkey point-of-care testing solution that combines point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). The HealthTab also has capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab platform transforms pharmacies into community point-of-care diagnostic centers.

TSXV:AVCR - Post by User

Avricore Health Inc

<< Previous

Bullboard Posts

Next >>

(2127)
•••

Post by lscfaon Nov 18, 2024 9:26pm

130 Views

Post# 36319027

Forecast

Co. says it will better off a year from now. Assuming more testing in the UK than Canada due to govt. reimbursement 2025 revenues will exceed 2024 revenues even with the redeployment of fewer devices by year end 2025.

Qtr ending	Deployed	Lease & service	Products sold	Revenue
Q4 25 (e)	500	375,000	1,500,000	1,875,000
Q3 25 (e)	300	225,000	900,000	1,125,000
Q2 25 (e)	100	75,000	300,000	375,000
Q1 25 (e)	300	225,000	300,000	525,000
Q4 24 (e)	800	600,000	400,000	1,000,000
Q3 24 (e)	800	600,000	400,000	1,000,000
Q2 24	781	581,166	464,040	1,045,206
Q1 24	775	563,487	560,820	1,124,307
Q4 23	693	475,579	878,824	1,354,403
Q3 23	635	406,119	547,335	953,454
Q2 23	541	387,206	160,843	548,049
Q1 23	532	311,001	318,240	629,241
Q4 22	416	140,685	836,550	977,235
Q3 22	166	52,290	519,938	572,228
Q2 22	53	14,940	161,235	176,175
Q1 22	53	14,491	28,245	42,736
Q4 21	20	0	35,190	35,190